A histomorphometric comparison of the effects of heparin and low- molecular-weight heparin on cancellous bone in rats

Blood

Volumn 89, Issue 9, 1997, Pages 3236-3242

  Muir, Jeffrey M ^a   Hirsh, Jack ^a   Weitz, Jeffrey I ^a,b   Andrew, Maureen ^a,b   Young, Edward ^a   Shaughnessy, Stephen G ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b HEART AND STROKE FOUNDATION OF CANADA   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PYRIDINOLINE; TINZAPARIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCELLOUS BONE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GROWTH PLATE; HEPARINIZATION; MOLECULAR WEIGHT; MORPHOMETRICS; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPENIA; PRIORITY JOURNAL; RAT; RISK ASSESSMENT;

EID: 0030954285     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.9.3236     Document Type: Article

References (38)

1. Hirsh J: Heparin. N Engl J Med 324:1565, 1991
2. Levine MN, Hirsh J and Kelton JG: Heparin-induced bleeding. in Lane D, Lindahl U (eds): Heparin. London, UK, Edward Arnold, 1989, p 517
3. Mant MJ, O'Brien BD, Thong KL, Hammond GW, Birtwhistle RV, Grace MG: Hemorrhagic complications of heparin therapy. Lancet 1:1133, 1977
4. Kelton JG, Levine MN: Heparin induced thrombocytopenia. Semin Thromb Haemost 12:59, 1986
5. Avioli LV: Heparin induced osteoporosis: An appraisal. Adv Exp Med Biol 52:375, 1975
6. Griffith CC, Nichols G, Asher JD, Flanagan B: Heparin osteoporosis. J Am Med Assoc 193:85, 1965
7. Jaffe MD, Willis PW: Multiple fractures associated with long term sodium heparin therapy. J Am Med Assoc 193:152, 1965
8. Dahlman TC, Sjoberg HE, Ringertz H: Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 170:1315, 1994
9. Murphy MS, John PR, Mayer AD, Buckels JAC, Kelly DA: Heparin therapy and bone fractures. Lancet 340:1098, 1992
10. Monreal M, Olive A, Lafoz E, Del Rio L: Heparins, coumarin, and bone density. Lancet 338:706, 1991
11. Rupp WM, McCarthy HB, Rohde TD, Blackshear PJ, Goldenberg FJ, Buchwald H: Risk of osteoporosis in patients treated with long-term intravenous heparin. Curr Probl Surg 39:419, 1982
12. Barbour LA, Kick SD, Steiner JF, LoVerde ME, Heddleston LN, Lear JL, Baron AE, Barton PL: A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 170:862, 1994
13. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C: Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 71:7, 1994
14. Dahlman TC: Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 168:1265, 1993
15. Frydman A, Bara L, Leroux Y, Woler M, Chauliac F, Duchier J, Samama M: The antithrombotic activity and pharmacokinetics of Enoxaparin, a low molecular weight heparin, in man given a single subcutaneous dose of 20 up to 80 mg. J Clin Pharmocol 28:608, 1988
16. Bara L, Billaud E, Gramond G, Kher A, Samama M: Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 39:631, 1985
17. Young E, Prins M, Levine MN, Hirsh J: Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 67:639, 1992
18. Barzu T, Molho P, Tobelem G, Petitou M, Caen JP: Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture. Nouv Rev Fr Hematol 26:243, 1984
19. Barzu T, Van Rijn JLMC, Petitou M, Tobelem G, Caen JP: Heparin degradation in the endothelial cells. Thromb Res 47:601, 1987
20. Vitoux JF, Mathieu JF, Roncato M, Fiessinger JN, Aiach M: Heparin associated thrombocytopenia: Treatment with low molecular weight heparin. Thromb Haemost 55:37, 1986
21. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG: Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 332:1330, 1995
22. Shaughnessy SG, Young E, Deschamps P, Hirsh J: The effects of low molecular-weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86:1368, 1995
23. Cochran DL: Glycosaminoglycan stimulation of calcium release from mouse calvariae. Specificity for hyaluronic acid and dermatan sulfate. Calcif Tissue Int 41:79, 1987
24. Lenaers-Claeys G, Vaes G: Collagenase, procollagenase and bone resorption. Effects of heparin, parathyroid hormone and calcitonin. Biochim Biophys Acta 584:375, 1979
25. Muir JM, Andrew M, Hirsh J, Weitz JI, Young E, Deschamps P, Shaughnessy SG: Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 88:1314, 1996
26. Murakami H, Nakamura T, Tsurukami H, Abe M, Barbier A, Suzuki K: Effects of Tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy. J Bone Miner Res 9:1355, 1994
27. Jee WSS, Inoue J, Jee KW, Haba T: Histomorphometric assay of the growing long bone, in Takahashi H (ed): Handbook of Bone Morphology. Niigata City, Japan, Nishimura, pp 101
28. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR: Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595, 1987
29. Hurley MM, Kream BE, Raisz LG: Structural determinants of the capacity of heparin to inhibit collagen synthesis in 21-day fetal rat calvariae. J Bone Miner Res 5:1127, 1990
30. Shibata Y, Abiko Y, Goto K, Moriya Y, Takiguchi H: Heparin stimulates the collagen synthesis in mineralized cultures of the osteoblast-like cell line, MC3T3-E1. Biochem Intern 28:335, 1992
31. Crisp AJ, Wright JK, Hazleman BL: Effects of heparin, histamine, and salmon calcitonin on mouse calvarial bone resorption. Ann Rheum Dis 45:422, 1986
32. Monreal M, Vinas L, Monreal L, Lavin S, Lafoz E, Angles AM: Heparin-related osteoporosis in rats. Haemostasis 20:204, 1990
33. Matzsch T, Bergqvist D, Hedner U, Nilsson B, Ostergaard P: Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats. Thromb Haemost 63:505, 1990
34. Rodan GA, Martin TJ: Role of osteoblasts in hormonal control of bone resorption - A hypothesis. Calcif Tissue Int 33:349, 1981
35. Braidman IP, Anderson DC, Jones CJP, Weiss JB: Separation of two bone populations from fetal rat calvaria and a study of their responses to parathyroid hormone and calcitonin. J Endocrinol 99:387, 1983
36. McSheehy PMJ, Chambers TJ: Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 118:824, 1986
37. Turner RT. Cancellous bone turnover in growing rats: Time-dependent changes in association between calcein label and osteoblasts. J Bone Miner Res 9:1419, 1994
38. Turner RT, Evans GL, Wakley GK: Reduced chondroclast differentiation results in increased cancellous bone volume in estrogen-treated growing rats. Endocrinology 134:461, 1994